Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

Omiloxetine (omiloextinum, omiloxetino INN)[1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]

Rafael Foguet also patented Abaperidone.

References

  1. ^ "Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 212–213. 1996.
  2. ^ Terencio J (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
  3. ^ De Lecea C (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.


Categories
Table of Contents